These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 20668631)

  • 41. Tissue velocity echocardiography shows early improvement in diastolic function with irbesartan and atenolol therapy in patients with hypertensive left ventricular hypertrophy. Results form the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA).
    Müller-Brunotte R; Kahan T; Malmqvist K; Ring M; Edner M
    Am J Hypertens; 2006 Sep; 19(9):927-36. PubMed ID: 16942935
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension.
    Okin PM; Wachtell K; Devereux RB; Harris KE; Jern S; Kjeldsen SE; Julius S; Lindholm LH; Nieminen MS; Edelman JM; Hille DA; Dahlöf B
    JAMA; 2006 Sep; 296(10):1242-8. PubMed ID: 16968848
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effects of losartan on left ventricular mass: a three-year follow-up in elderly hypertensives with myocardial hypertrophy despite successful conventional antihypertensive treatment.
    Moroni C; Tolone S; Lopreiato F; Scrofani AR; Bossini A; Affricano C; Cassone R; Gaudio C
    Eur Rev Med Pharmacol Sci; 2017 Mar; 21(6):1323-1328. PubMed ID: 28387895
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy.
    Dahlof B; Zanchetti A; Diez J; Nicholls MG; Yu CM; Barrios V; Aurup P; Smith RD; Johansson M;
    J Hypertens; 2002 Sep; 20(9):1855-64. PubMed ID: 12195129
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Enalapril and losartan reduced cardiac mass and improved coronary hemodynamics in SHR.
    Nunez E; Hosoya K; Susic D; Frohlich ED
    Hypertension; 1997 Jan; 29(1 Pt 2):519-24. PubMed ID: 9039153
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Losartan and the LIFE-study. Antihypertensive treatment with AT1-receptor antagonist].
    Kjeldsen SE; Omvik P
    Tidsskr Nor Laegeforen; 1996 Feb; 116(4):504-7. PubMed ID: 8644056
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Apoptosis during regression of cardiac hypertrophy in spontaneously hypertensive rats. Temporal regulation and spatial heterogeneity.
    Tea BS; Dam TV; Moreau P; Hamet P; deBlois D
    Hypertension; 1999 Aug; 34(2):229-35. PubMed ID: 10454446
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects of antihypertensive therapy on cardiac sodium/hydrogen ion exchanger activity and hypertrophy in spontaneously hypertensive rats.
    Alvarez BV; Ennis IL; De Hurtado MC; Cingolani HE
    Can J Cardiol; 2002 Jun; 18(6):667-72. PubMed ID: 12107424
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Left ventricular hypertrophy: how to influence an important risk factor in hypertension.
    Agabiti-Rosei E; Muiesan ML
    J Hypertens Suppl; 1998 Jan; 16(1):S53-8. PubMed ID: 9534098
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Angiotensin-converting enzyme inhibitors and effects on left ventricular hypertrophy.
    Dahlöf B
    Blood Press Suppl; 1994; 2():35-40. PubMed ID: 8061844
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy.
    Solomon SD; Appelbaum E; Manning WJ; Verma A; Berglund T; Lukashevich V; Cherif Papst C; Smith BA; Dahlöf B;
    Circulation; 2009 Feb; 119(4):530-7. PubMed ID: 19153265
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of actions of irbesartan versus atenolol on cardiac repolarization in hypertensive left ventricular hypertrophy: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation Versus Atenolol (SILVHIA).
    Malmqvist K; Kahan T; Edner M; Bergfeldt L
    Am J Cardiol; 2002 Nov; 90(10):1107-12. PubMed ID: 12423712
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Experimental evidence for effects of ramipril on cardiac and vascular hypertrophy beyond blood pressure reduction.
    Linz W; Gohlke P; Unger T; Schölkens BA
    Arch Mal Coeur Vaiss; 1995 Feb; 88 Spec No 2():31-4. PubMed ID: 7646309
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Reversal of interstitial fibroblast hyperplasia via apoptosis in hypertensive rat heart with valsartan or enalapril.
    Der Sarkissian S; Marchand EL; Duguay D; Hamet P; deBlois D
    Cardiovasc Res; 2003 Mar; 57(3):775-83. PubMed ID: 12618239
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparative effects of three sites of renin-angiotensin blockade on the regression of left ventricular hypertrophy in spontaneously hypertensive rats.
    Zhang Q; Kohara K; Qui HY; Hiwada K
    Am J Ther; 1997; 4(5-6):199-202. PubMed ID: 10423611
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Differential regulation of cardiac adrenomedullin and natriuretic peptide gene expression by AT1 receptor antagonism and ACE inhibition in normotensive and hypertensive rats.
    Magga J; Kalliovalkama J; Romppanen H; Vuolteenaho O; Pörsti I; Kähönen M; Tolvanen JP; Ruskoaho H
    J Hypertens; 1999 Nov; 17(11):1543-52. PubMed ID: 10608466
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Arterial responses in vitro and plasma digoxin immunoreactivity after losartan and enalapril treatments in experimental hypertension.
    Kalliovalkama J; Kähönen M; Tolvanen JP; Wu X; Voipio J; Pekki A; Doris PA; Ylitalo P; Pörsti I
    Pharmacol Toxicol; 2000 Jan; 86(1):36-43. PubMed ID: 10720105
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Regression of left ventricular hypertrophy: do antihypertensive classes differ?
    Sheridan DJ
    J Hypertens Suppl; 2000 Jul; 18(3):S21-7. PubMed ID: 10952084
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparative efficacy of different types of antihypertensive drugs in reversing left ventricular hypertrophy as determined with echocardiography in hypertensive patients: A network meta-analysis of randomized controlled trials.
    Chen JS; Pei Y; Li CE; Li YN; Wang QY; Yu J
    J Clin Hypertens (Greenwich); 2020 Dec; 22(12):2175-2183. PubMed ID: 33190366
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group.
    Dahlöf B; Devereux R; de Faire U; Fyhrquist F; Hedner T; Ibsen H; Julius S; Kjeldsen S; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H
    Am J Hypertens; 1997 Jul; 10(7 Pt 1):705-13. PubMed ID: 9234823
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.